Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

News Daily News

AHA Plugs ‘Dietary Patterns’ Over Dietary Cholesterol Targets

Yael L. Maxwell

December 26, 2019

News Daily News

NT-proBNP May Hold the Key to Predicting Cardiac Risk Before Noncardiac Surgery

Yael L. Maxwell

December 24, 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News Daily News

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

Yael L. Maxwell

December 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2019

Shelley Wood

November 29, 2019

News Daily News

Apple Watch as an ECG? Feasible, May Prove Useful in Emergencies

Yael L. Maxwell

November 28, 2019

News Daily News

Physicians as Patients: Better Health, Less CV Prevention Among Ontario Doctors Than General Public

Yael L. Maxwell

November 26, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Yael L. Maxwell

October 10, 2019

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

Advertisement

AHA Plugs ‘Dietary Patterns’ Over Dietary Cholesterol Targets

NT-proBNP May Hold the Key to Predicting Cardiac Risk Before Noncardiac Surgery

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

TCTMD’s Top 10 Most Popular Stories for November 2019

Apple Watch as an ECG? Feasible, May Prove Useful in Emergencies

Physicians as Patients: Better Health, Less CV Prevention Among Ontario Doctors Than General Public

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Statins Started in Kids With FH Provide Benefits in Adulthood

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content